On the public citation graph

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

https://doi.org/10.1016/j.lungcan.2020.11.013
0 signed · 85 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.cllc.2018.01.004openalex-snapshot
Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study
inferredcites →https://doi.org/10.1016/j.jtho.2016.05.021openalex-snapshot
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
inferredcites →https://doi.org/10.1016/j.jtho.2017.10.029openalex-snapshot
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
inferredcites →https://doi.org/10.1016/j.jtho.2018.10.020openalex-snapshot
OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
inferredcites →https://doi.org/10.1016/j.jtho.2019.01.006openalex-snapshot
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)71180-5openalex-snapshot
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
inferredcites →https://doi.org/10.1016/s1470-2045(19)30407-3openalex-snapshot
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
inferredcites →https://doi.org/10.1038/sj.bjc.6604721openalex-snapshot
Emerging ethnic differences in lung cancer therapy
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/annonc/mdv532.01openalex-snapshot
417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
inferredcites →https://doi.org/10.1093/annonc/mdw326openalex-snapshot
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdy041openalex-snapshot
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
inferredcites →https://doi.org/10.1093/annonc/mdy275openalex-snapshot
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdy511.003openalex-snapshot
Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
inferredcites →https://doi.org/10.1093/annonc/mdy554openalex-snapshot
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
inferredcites →https://doi.org/10.1097/jto.0b013e3182199c03openalex-snapshot
Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials
inferredcites →https://doi.org/10.1111/cas.13932openalex-snapshot
KEYNOTE ‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer
inferredcites →https://doi.org/10.1200/jco.2017.74.3062openalex-snapshot
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
inferredcites →https://doi.org/10.1634/theoncologist.2019-io-s1-s02openalex-snapshot
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.5732/cjc.011.10106openalex-snapshot
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4571985openalex-extracted
Role of ICIs-Based Therapies and Bevacizumab for Advanced Wild-Type Non-Squamous NSCLC in the First-Line Setting: A Bayesian Network Analysis
inferred← citeshttps://doi.org/10.1002/cam4.7080openalex-snapshot
East Asian patients who received immunotherapy‐based therapy associated with improved survival benefit in advanced non‐small cell lung cancer: An updated meta‐analysis
inferred← citeshttps://doi.org/10.1002/ctm2.1613openalex-snapshot
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
inferred← citeshttps://doi.org/10.1007/s00109-024-02450-8openalex-snapshot
PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s00262-022-03259-5openalex-snapshot
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104357openalex-snapshot
Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
inferred← citeshttps://doi.org/10.1016/j.eclinm.2021.100990openalex-snapshot
The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102156openalex-snapshot
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
inferred← citeshttps://doi.org/10.1016/j.eclinm.2025.103081openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.05.024openalex-snapshot
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.12.009openalex-snapshot
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.prp.2023.154470openalex-snapshot
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
inferred← citeshttps://doi.org/10.1038/s41416-026-03408-yopenalex-snapshot
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
inferred← citeshttps://doi.org/10.1038/s41591-024-02808-yopenalex-snapshot
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
inferred← citeshttps://doi.org/10.1080/17512433.2023.2188194openalex-snapshot
A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
inferred← citeshttps://doi.org/10.1080/21645515.2024.2429893openalex-snapshot
The role of artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis
inferred← citeshttps://doi.org/10.1093/jncics/pkaf085openalex-snapshot
Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1097/cad.0000000000001569openalex-snapshot
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study
inferred← citeshttps://doi.org/10.1097/coc.0000000000001077openalex-snapshot
Bombarding Oligoprogression
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-049123openalex-snapshot
Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis
inferred← citeshttps://doi.org/10.1142/s0192415x26500059openalex-snapshot
Research Progress on Combination Therapies Based on PD-1/PD-L1 Blockade Against Malignancies and the Adjuvant Effects of Traditional Chinese Medicine
inferred← citeshttps://doi.org/10.1155/2022/2483816openalex-snapshot
Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
inferred← citeshttps://doi.org/10.1177/10732748221107590openalex-snapshot
PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1177/15330338241246651openalex-snapshot
Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study
inferred← citeshttps://doi.org/10.1177/17588359211029826openalex-snapshot
Research progress in immune checkpoint inhibitors for lung cancer in China
inferred← citeshttps://doi.org/10.1186/s12885-021-08662-2openalex-snapshot
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
inferred← citeshttps://doi.org/10.1186/s12943-023-01926-4openalex-snapshot
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer
inferred← citeshttps://doi.org/10.1186/s40246-026-00968-1openalex-snapshot
MiR-4788 promotes NSCLC progression by targeting DLG5 to enhance mitochondrial function
inferred← citeshttps://doi.org/10.21203/rs.3.rs-855827/v1openalex-snapshot
Comparison of Chemotherapy With PD-1/L1 or CTLA-4 Inhibitors Alone Or In Combination In Advanced Or Metastatic Non-Small Cell Lung Cancer: A Meta- Analysis
inferred← citeshttps://doi.org/10.21203/rs.3.rs-9240131/v1openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trials
inferred← citeshttps://doi.org/10.2147/btt.s489363openalex-snapshot
Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
inferred← citeshttps://doi.org/10.2174/1386207326666230808112656openalex-snapshot
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.2217/fon-2022-0861openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
inferred← citeshttps://doi.org/10.2217/imt-2023-0307openalex-snapshot
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
inferred← citeshttps://doi.org/10.3310/gjnw3422openalex-snapshot
Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1004351openalex-snapshot
Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1094414openalex-snapshot
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1340979openalex-snapshot
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1493877openalex-snapshot
Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1595382openalex-snapshot
Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.3389/fonc.2021.745493openalex-snapshot
PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China
inferred← citeshttps://doi.org/10.3389/fonc.2022.827050openalex-snapshot
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies
inferred← citeshttps://doi.org/10.3389/fonc.2022.859892openalex-snapshot
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework
inferred← citeshttps://doi.org/10.3389/fonc.2022.883514openalex-snapshot
Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
inferred← citeshttps://doi.org/10.3389/fonc.2022.955440openalex-snapshot
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2023.1107631openalex-snapshot
Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
inferred← citeshttps://doi.org/10.3389/fonc.2026.1847284openalex-snapshot
Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia
inferred← citeshttps://doi.org/10.3389/fphar.2022.880280openalex-snapshot
Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
inferred← citeshttps://doi.org/10.3389/fphar.2022.955701openalex-snapshot
Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fphar.2023.1093194openalex-snapshot
Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fpubh.2023.1051484openalex-snapshot
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
inferred← citeshttps://doi.org/10.3390/cancers13194906openalex-snapshot
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
inferred← citeshttps://doi.org/10.3390/cancers14010109openalex-snapshot
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
inferred← citeshttps://doi.org/10.3390/cancers16020340openalex-snapshot
Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/ijms241914521openalex-snapshot
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
inferred← citeshttps://doi.org/10.3390/jcm11247523openalex-snapshot
Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.3390/life11111277openalex-snapshot
Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/pharmaceutics16060732openalex-snapshot
Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2022.101.25openalex-snapshot
[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer in the Elderly (2022 Edition)].
inferred← citeshttps://doi.org/10.4103/jalh.jalh_24_24openalex-snapshot
Comparison of Nivolumab with Docetaxel in the Treatment of Advanced Squamous Cell Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.54033/cadpedv22n5-051openalex-snapshot
Eficiência dos inibidores de PD-1 e PD-L1 no tratamento do carcinoma pulmonar de não pequenas células, uma revisão integrativa
inferred← citeshttps://doi.org/10.6084/m9.figshare.16530131openalex-snapshot
Additional file 1 of The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.